TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3878905
Drug: 1,25(OH)2D3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 treatment for a mean of 16.8 ± 6.4 months
Study: 24826396
Drug: Novel ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel ALA (5-aminolevulinic acid) treatment, 2 treatments 2 weeks apart
Study: 16081585
Drug: Montelukast (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (oral, 10 mg/day) combined with inhaled Budesonide (400 microg/bid)
Study: 12069111
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy based on idebenone
Study: 12069111
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 plus Vitamin E administration
Study: 9578859
Drug: Usual breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual breast screening invitation accompanied by a self administered questionnaire
Study: 1804010
Drug: Cefepime (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2.0 g intravenously twice daily for 4 to 28 days)
Study: 1804010
Drug: Ceftazidime (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2.0 g every 8 h)
Study: 6228347
Drug: Intranasal ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ipratropium
Study: 31496381
Drug: Ultrasound-guided quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided quadratus lumborum block (QLB) with 10 ml of 0.5% bupivacaine and 10 ml of 2% lidocaine before ESWL
Study: 26444149
Drug: 0.3 μg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg.kg(‐1) dexmedetomidine
Study: 26444149
Drug: 1 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg(‐1) propofol
Study: 15794869
Drug: Oral chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chlorambucil at a dose of 8 mg/m² (6 mg/m² for those > 75 years of age) for 10 days every 28 days to a maximum of 12 cycles
Study: 15794869
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intravenous (I.V.) fludarabine at a dose of 40 mg/m² orally or 25 mg/m² I.V. (30 mg/m² orally or 20 mg/m² I.V. for those > 75 years of age) for 5 days every 28 days to a maximum of 6 cycles
Study: 12872394
Drug: Fluticasone inhalation
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone inhalation combined with XQLD
Study: 12872394
Drug: Fluticasone inhalation
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone inhalation
Study: 9160568
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine (3, 5, and 7 mg/kg)
Study: 2690914
Drug: Oral fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluorouracil 500 mg, methotrexate 25 mg and chlorambucil 10 mg p.o. on day 1 and fluorouracil 500 mg and chlorambucil 10 mg p.o. on day 2 (LMF) every 21 days for eight cycles.
Study: 971343
Drug: Secholex (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secholex (15 g/day)
Study: 971343
Drug: Secholex (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secholex (9 g/day)
Study: 25781384
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg IV
Study: 16365070
Drug: Regular wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular wheat bread and cholecalciferol supplement (vitamin D control)
Study: 10827226
Drug: MARS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MARS treatment in addition to hemodiafiltration (HDF) and standard medical therapy
Study: 10827226
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (HDF and standard medical treatment alone)
Study: 8770960
Drug: Supraphysiologic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiologic dose B-vitamin supplementation (15 mg folic acid/day, 100 mg B-6/day, 1 mg B-12/day)
Study: 8770960
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (1 mg folic acid, 10 mg B-6, 12 micrograms B-12)
Study: 8770960
Drug: Supraphysiologic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiologic dose B-vitamin supplementation
Study: 1608903
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of alcohol (94%) in 75 ml of orange juice
Study: 1608903
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of orange juice
Study: 20373908
Drug: I-neb AAD
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-neb AAD System with Target Inhalation Mode (TIM)
Study: 12449165
Drug: MPA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (30 mg b.i.d.)
Study: 12449165
Drug: ACET (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACET (250 mg b.i.d.)
Study: 8523872
Drug: Duraflo II
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraflo II bonded heparin coated circuit
Study: 1686197
Drug: Novel anxiolytic/hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel anxiolytic/hypnotic compound
Study: 7145555
Drug: High-dose split-product
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose split-product vaccine (SPV) containing 7, 7, and 60 micrograms of hemagglutinins (HA)
Study: 7145555
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose split-product vaccine (SPV) containing 7, 7, and 7 micrograms of HA
Study: 7145555
Drug: High-dose split-product
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose split-product vaccine (SPV)
Study: 7145555
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose split-product vaccine (SPV)
Study: 31478938
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (PCS) with propofol (PCS-G group)
Study: 28176175
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant therapy
Study: 21893151
Drug: 2-doses of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-doses of PCV7(CRM197)
Study: 21893151
Drug: 2+1-doses of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2+1-doses of PCV7(CRM197)
Study: 14706012
Drug: Cholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic therapy (bethanechol chloride 60 mg/day or distigmine bromide 15 mg/day)
Study: 14706012
Drug: Alpha-blocker therapy
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker therapy (urapidil 60 mg/day)
Study: 14706012
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cholinergic drug and alpha-blocker)
Study: 14706012
Drug: Cholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic therapy (control)
Study: 14706012
Drug: Alpha-blocker therapy
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker therapy (control)
Study: 11676116
Drug: Butenafine (1%)
DrugBank: Butenafine (DB01091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butenafine (1%) cream applied for 4 weeks for tinea pedis and 2 weeks for tinea cruris and tinea corporis
Study: 11038765
Drug: Intraperitoneal (i.p.)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (i.p.) carboplatin chemotherapy
Study: 11038765
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) carboplatin chemotherapy
Study: 7946939
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN; 20 mg twice daily for 2 weeks)
Study: 31838920
Drug: Amoxicillin/clavulanate for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate for 4 weeks and a short course of oral steroids
Study: 11095598
Drug: Tetracycline (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (6-week course, twice daily)
Study: 3922048
Drug: CaNa2EDTA infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CaNa2EDTA infusion during the first 2 days after admission
Study: 3922048
Drug: Normal conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal conservative treatment
Study: 30019751
Drug: Perioperative aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative aspirin
Study: 26418211
Drug: HiP (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiP (high protein): parenteral nutrition = 3.5 AA, enteral nutrition = 4.6 protein g·kg·day
Study: 26418211
Drug: StP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: StP (standard protein): parenteral nutrition = 2.5 AA, enteral nutrition = 3.6 protein g·kg·day
Study: 21155337
Drug: Levobupivacaine-fentanyl (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine-fentanyl (3 mg of 0.1% levobupivacaine plus 10 microg of fentanyl)
Study: 21155337
Drug: Lidocaine-fentanyl (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-fentanyl (18 mg of 0.6% lidocaine plus 10 microg of fentanyl)
Study: 15295694
Drug: Canarypox HIV‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canarypox HIV‐1 vaccine
Study: 9831304
Drug: Naltrexone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (75 mg daily for 12 weeks)
Study: 2751143
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication (meperidine 3.0 mg/kg, pentobarbital 4.0 mg/kg)
Study: 2751143
Drug: Intramuscular medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular medication (morphine 0.1 mg/kg, pentobarbital 4.0 mg/kg)
Study: 23074076
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (RT) intervention for 8 weeks, 8 exercises, 1 set of 10 repetitions at perceived exertion of 5-6, performed twice a week
Study: 19709691
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose infusion (0.75 g glucose per kilogram body weight for 2.5 hours)
Study: 15716204
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg daily for 4 weeks, followed by flexible dosing (5 mg or 10 mg)
Study: 15716204
Drug: Solifenacin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin treatment
Study: 12072586
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg or 20 mg lercanidipine
Study: 10086838
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg reboxetine orally
Study: 10086838
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg reboxetine as an intravenous bolus
Study: 7985892
Drug: Zidovudine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 600 mg/d
Study: 7985892
Drug: Zalcitabine, 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalcitabine, 2.25 mg/d
Study: 7985892
Drug: Zidovudine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 600 mg/d, and zalcitabine, 2.25 mg/d
Study: 7985892
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (zidovudine and zalcitabine)
Study: 7985892
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (for patients with 50 to 150 CD4 cells/mm3 or fewer than 50 CD4 cells/mm3)
Study: 2154407
Drug: Enalapril (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (initial dose, long-term treatment for 1 and 6 weeks)
Study: 2154407
Drug: Enalapril (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (after first dose)
Study: 31816842
Drug: Euglena gracilis
Normalized name: EUGLENA GRACILIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglena gracilis fermentate (BG) 367 mg
Study: 17845651
Drug: 4% modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% modified gelatine solution
Study: 15218813
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate treatment over 3 years
Study: 11451751
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg daily for 6 weeks)
Study: 2563695
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course metronidazole rectal suppositories
Study: 26063503
Drug: Clopidogrel 300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300/75 mg regimen
Study: 26063503
Drug: Clopidogrel 600/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600/150 mg regimen
Study: 26063503
Drug: Clopidogrel 300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300/75 mg regimen and 600/150 mg regimen
Study: 23151750
Drug: Usual MAP
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual MAP treatment goal (102‐107 mm Hg)
Study: 23151750
Drug: Low MAP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low MAP treatment goal (≤92 mm Hg)
Study: 18485575
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate 400 mg bid (C400)
Study: 18485575
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate 200 mg bid (C200)
Study: 30832581
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (control group).
Study: 9342586
Drug: Nicotine inhalation
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhalation at 30 degrees C
Study: 9342586
Drug: Nicotine inhalation
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhalation at 40 degrees C
Study: 9342586
Drug: Nicotine inhalation
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhalation at 20 degrees C
Study: 8376688
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 to 20 mg/day)
Study: 3757162
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg dexamethasone i.v.
Study: 20363993
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no atorvastatin therapy)
Study: 19005437
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (700 mg of flavonoids/day for one week)
Study: 16161727
Drug: Psychotherapy (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (8 sessions of cognitive behavioral therapy) plus antidepressant pharmacotherapy over 3 months
Study: 11123120
Drug: NTG patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG patch (n = 6)
Study: 11123120
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (n = 6)
Study: 11123120
Drug: NTG patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG patch (n = 5, at H4)
Study: 11123120
Drug: NTG patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG patch (n = 5, at H23)
Study: 11123120
Drug: NTG patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG patch (n = 5)
Study: 7841703
Drug: Buserelin intranasal
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin intranasal spray (group A)
Study: 3234301
Drug: Al-Mg-silicate preparation
Normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Mg-silicate preparation (MegalacR) administered 45 min after the meal
Study: 3234301
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PI without antacid
Study: 17541571
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral morphine
Study: 15504996
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (Exubera) plus bedtime Ultralente
Study: 15504996
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin regimen (two to three injections of regular and NPH insulin)
Study: 15504996
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (Exubera)
Study: 11139801
Drug: Intravenous glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycoprotein IIb/IIIa antagonists
Study: 8620374
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching gel (2 hours exposure)
Study: 8620374
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching gel (7 hours exposure)
Study: 30417697
Drug: Expedited therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited therapy
Study: 30399122
Drug: Naloxone 8
Normalized name: naloxone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 8 mg
Study: 23334070
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg ponezumab
Study: 23334070
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg ponezumab
Study: 23334070
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ponezumab
Study: 23334070
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg ponezumab
Study: 23334070
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ponezumab
Study: 22334928
Drug: sinuforte (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: sinuforte (1.3 mg per procedure, once daily for 7 days)
Study: 12642739
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, amoxicillin 1 g twice daily for 1 week (OAzAm group, n = 80)
Study: 12642739
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, tinidazole 500 mg twice daily for 3 days (OAzT group, n = 80)
Study: 10699899
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg intravenous infusion every 3-4 weeks)
Study: 9524466
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride (AmF) solution containing 1% fluoride, biannual applications for 5 years
Study: 9524466
Drug: Placebo solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution, biannual applications for 5 years
Study: 9524466
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride (AmF) solution containing 1% fluoride
Study: 8105512
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg i.v. bolus)
Study: 8105512
Drug: Famotidine (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (without hG infusion)
Study: 3513684
Drug: Hormone withdrawal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone withdrawal after tamoxifen
Study: 26139093
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (30 min twice a week)
Study: 27247226
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks
Study: 24051659
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg · d(‐1), n = 8 subjects)
Study: 23328294
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus local chemotherapeutic perfusion of cisplatin 40 mg weekly for 2 weeks
Study: 23328294
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus local chemotherapy
Study: 19849696
Drug: 0.06% retinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% retinyl retinoate applied twice daily for 12 weeks
Study: 19849696
Drug: 0.06% retinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% retinyl retinoate applied twice daily for 8 weeks
Study: 17855671
Drug: Idraparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux (2.5 mg once-weekly for 6 months)
Study: 17855671
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (initial treatment)
Study: 30939096
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months
Study: 30422235
Drug: Lanreotide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n=153)
Study: 26987626
Drug: β2‐1 Fructan
Approvals — FDA: no, EMA: no, PMDA: no
Description: β2‐1 Fructan supplementation (3×5 g/d)
Study: 24206841
Drug: Paracetamol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol administration for fever (≥37·5°C)
Study: 24206841
Drug: Insulin administration
Normalized name: insulin administration supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin administration for hyperglycemia (>11 mmol/L)
Study: 22502814
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Helium Neon (He‐Ne) Laser therapy (λ=632.8 nm, P=24 mW, ED=3.5 J/cm(2))